<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468075</url>
  </required_header>
  <id_info>
    <org_study_id>201802800 (Phase II)</org_study_id>
    <nct_id>NCT03468075</nct_id>
  </id_info>
  <brief_title>Gemcitabine Plus Ascorbate for Sarcoma in Adults</brief_title>
  <official_title>A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohammed Milhem, MBBS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Iowa Adolescent and Young Adult (AYA) Cancer Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Baldrick's Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll patients who have a diagnosis of locally advanced, unresectable or&#xD;
      metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's&#xD;
      sarcoma) from any site.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll male and female patients 18 years old or older who have a diagnosis of&#xD;
      locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except GIST and&#xD;
      Kaposi's) from any site. A minimum of 1 prior chemotherapy regimen, including adjuvant and&#xD;
      neo-adjuvant therapy for the treatment of sarcoma, must have been given. Patients eligible&#xD;
      for an anthracycline should have received a prior anthracycline containing regimen. Patients&#xD;
      who decline or are not eligible for anthracycline treatment may be considered for this&#xD;
      protocol as a first line treatment. Patients with a diagnosis of liposarcoma should also have&#xD;
      received eribulin.&#xD;
&#xD;
      During screening, subjects will receive a test dose (15g) of ascorbate. If the test dose&#xD;
      results in any toxicity &gt;/= CTCAE grade 3 or a significant medical event in the opinion of&#xD;
      the principal investigator, the patient will be considered a screen failure.&#xD;
&#xD;
      Subjects who pass screening will then receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16&#xD;
      of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion&#xD;
      of ascorbate. Concomitant treatment will continue for at least 6 cycles. Patients whose&#xD;
      disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating&#xD;
      therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles&#xD;
      at the discretion of the investigator. Treatment will be terminated with progression of&#xD;
      disease. Disease will be assessed by CT of the chest, abdomen and pelvis or MRI of the lesion&#xD;
      every 2 cycles for progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopping rules met&#xD;
  </why_stopped>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Actual">October 19, 2020</completion_date>
  <primary_completion_date type="Actual">April 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>Every 2 months for first 6 months, then every 3 months up to 2 years post treatment</time_frame>
    <description>From first day of treatment to documented disease progression as described by RECIST 1.1 criteria. Results are provided in nominal categories (CR, PR, SD, PD) as per RECIST.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Every 2 months for first 6 months, then every 3 months up to 2 years post treatment</time_frame>
    <description>Time from start of therapy (day 1, cycle 1) to documented disease progression or death due to any cause. Progression will be defined using the RECIST 1.1 guidelines. Results are provided in nominal categories (CR, PR, SD, PD) as per RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Every 2 months for first 6 months, then every 3 months up to 2 years post treatment</time_frame>
    <description>Time from start of therapy (day 1, cycle 1) to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AE) Per CTCAE 4.03</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Categorize and quantify adverse events from start of therapy (day 1, cycle 1) to end of study per (CTCAE) version 4.03.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Sarcoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Unresectable Soft Tissue Sarcoma</condition>
  <condition>Metastatic Bone Tumor</condition>
  <condition>Bone Sarcoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine + High-Dose Ascorbate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbate</intervention_name>
    <description>Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle</description>
    <arm_group_label>Gemcitabine + High-Dose Ascorbate</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
    <other_name>Vitamin C</other_name>
    <other_name>Pharmacological ascorbate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered on Days 1, 8 and 15, after the infusion of ascorbate</description>
    <arm_group_label>Gemcitabine + High-Dose Ascorbate</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged ≥ 18 years old&#xD;
&#xD;
          2. ECOG Performance Status of ≤ 2&#xD;
&#xD;
          3. Ability to provide written informed consent obtained prior to participation in the&#xD;
             study and any related procedures being performed&#xD;
&#xD;
               -  Patients must meet the following laboratory criteria:&#xD;
&#xD;
               -  Hematology:&#xD;
&#xD;
               -  Neutrophil count of &gt;1500/mm3&#xD;
&#xD;
               -  Platelet count of &gt; 100,000/mm3L&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL (transfusion to meet eligibility allowed)&#xD;
&#xD;
               -  Biochemistry:&#xD;
&#xD;
               -  AST/SGOT and ALT/SGPT ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x ULN if the&#xD;
                  transaminase elevation is due to disease involvement&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 5 x ULN&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min&#xD;
&#xD;
               -  Total serum calcium &gt;/= LLN or if calcium is below LLN then corrected calcium for&#xD;
                  serum albumin should be &gt;/= LLN&#xD;
&#xD;
               -  Serum potassium ≥ LLN&#xD;
&#xD;
               -  Serum sodium ≥ LLN&#xD;
&#xD;
               -  Serum albumin ≥ LLN or 3g/dl&#xD;
&#xD;
          4. Tolerate a 15g ascorbate infusion (screening dose)&#xD;
&#xD;
          5. Baseline MUGA or ECHO done only in subjects with prior doxorubicin exposure. The test&#xD;
             must demonstrate LVEF ≥ the lower limit of the institutional normal.&#xD;
&#xD;
          6. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within 7 days of the first administration of study treatment and must be willing to&#xD;
             use two methods of contraception one of them being a barrier method during the study&#xD;
             and for 3 months after last study drug administration&#xD;
&#xD;
          7. Any patient with the diagnosis of locally advanced, unresectable or metastatic soft&#xD;
             tissue or bone sarcoma (except GIST and Kaposi's) from any site. A minimum of 1 prior&#xD;
             chemotherapy regimen, including adjuvant and neo-adjuvant therapy for the treatment of&#xD;
             sarcoma. Patients eligible for an anthracycline should have received a prior&#xD;
             anthracycline containing regimen. Patients who decline or are not eligible for&#xD;
             anthracycline treatment may be considered for this protocol as a first line treatment.&#xD;
             Patients with a diagnosis of liposarcoma should also have received eribulin if they&#xD;
             received anthracycline-based therapy prior to eribulin. Patients with a diagnosis of&#xD;
             myxoid liposarcoma should have received trabectedin. Patients with angiosarcoma should&#xD;
             have received either taxol or docetaxel. Patients must have measurable disease defined&#xD;
             as at least 1 lesion ≥ 1cm in the greatest dimension.&#xD;
&#xD;
          8. Patients with metastatic bone sarcomas who have failed all available therapies that&#xD;
             have demonstrated clinical benefit. Available therapies include but not limited to&#xD;
             methotrexate, adriamycin and cisplatin for osteosarcoma and vincristine, adriamycin&#xD;
             and Cytoxan, ifosfamide, etoposide (VAC/IE)for Ewing's sarcoma.&#xD;
&#xD;
          9. Previous exposure to Gemcitabine will only be allowed if there is no residual toxicity&#xD;
             from previous treatments. Toxicity must be graded as 0 or 1 prior to study.&#xD;
&#xD;
         10. Patients must have had disease progression on or following their most recent treatment&#xD;
             regimen or on presentation for the first time with locally advanced unresectable or&#xD;
             metastatic disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. G6PD (glucose-6-phosphate dehydrogenase) deficiency&#xD;
&#xD;
          2. New York Heart Association (NYHA) Grade II or greater congestive heart failure (see&#xD;
             Appendix E)&#xD;
&#xD;
          3. History of myocardial infarction or unstable angina within 6 months prior to Day 1&#xD;
&#xD;
          4. History of stroke or transient ischemic attack within 6 months prior to Day 1&#xD;
&#xD;
          5. Known CNS disease, except for treated brain metastasis: Treated brain metastases are&#xD;
             defined as having no evidence of progression or hemorrhage after treatment and no&#xD;
             ongoing requirement for dexamethasone, as ascertained by clinical examination and&#xD;
             brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose)&#xD;
             are allowed. Treatment for brain metastases may include whole brain radiotherapy&#xD;
             (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or equivalent) or a combination as&#xD;
             deemed appropriate by the treating physician. Patients with CNS metastases treated by&#xD;
             neurosurgical resection or brain biopsy performed within 3 months prior to Day 1 will&#xD;
             be excluded&#xD;
&#xD;
          6. Actively receiving insulin or requiring fingerstick glucose monitoring at time of&#xD;
             ascorbate infusion (unless an exception is granted by the IND sponsor, medical&#xD;
             monitor, and the PI).&#xD;
&#xD;
          7. Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or&#xD;
             recent peripheral arterial thrombosis) within 6 months prior to Day 1&#xD;
&#xD;
          8. Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             therapeutic anticoagulation)&#xD;
&#xD;
          9. Pregnancy (positive pregnancy test) or lactation. Use of effective means of&#xD;
             contraception (men and women) in subjects of child-bearing potential&#xD;
&#xD;
         10. Patients who are on the following drugs and cannot have a drug substitution:&#xD;
             flecainide, methadone, amphetamines, quinidine, and chlorpropamide. High dose ascorbic&#xD;
             acid may affect urine acidification and, as a result, may affect clearance rates of&#xD;
             these drugs.&#xD;
&#xD;
         11. Other concurrent severe and/or uncontrolled medical conditions&#xD;
&#xD;
         12. Patients who have received chemotherapy or any investigational drug &lt; 2 weeks prior to&#xD;
             starting study drug or who have not recovered from side effects of such therapy.&#xD;
&#xD;
         13. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to Day 1 or anticipation of need for major surgical procedure during the course&#xD;
             of the study.&#xD;
&#xD;
         14. Concomitant use of any anti-cancer therapy or radiation therapy. Palliative radiation&#xD;
             therapy to non-target lesions is permitted.&#xD;
&#xD;
         15. Male patients whose sexual partners are WOCBP not using a double method of&#xD;
             contraception during the study and 3 months after the end of treatment. One of these&#xD;
             methods must be a condom.&#xD;
&#xD;
         16. Patients with a history of another primary malignancy within 2 years other than&#xD;
             curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin&#xD;
&#xD;
         17. Patients with known positivity for human immunodeficiency virus (HIV); baseline&#xD;
             testing for HIV is not required. High-dose ascorbate acid is a known CYP450 3A4&#xD;
             inducer, which results in lower serum levels of antiretroviral drugs.&#xD;
&#xD;
         18. Patients with any significant history of non-compliance to medical regimens or with&#xD;
             inability to grant a reliable informed consent.&#xD;
&#xD;
         19. Patients with GIST tumors and Kaposi's Sarcoma are excluded.&#xD;
&#xD;
         20. Patients with history of more than one symptomatic oxalate stone in the last 6 months&#xD;
             or visible stone in the kidney or ureter on screening CT scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Varun Monga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <results_first_submitted>November 16, 2020</results_first_submitted>
  <results_first_submitted_qc>November 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2020</results_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Varun Monga, MD</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>Soft tissue</keyword>
  <keyword>Ascorbate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03468075/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03468075/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine + High-Dose Ascorbate</title>
          <description>Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.&#xD;
Ascorbate: Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle&#xD;
Gemcitabine: Administered on Days 1, 8 and 15, after the infusion of ascorbate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine + High-Dose Ascorbate</title>
          <description>Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.&#xD;
Ascorbate: Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle&#xD;
Gemcitabine: Administered on Days 1, 8 and 15, after the infusion of ascorbate</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="52" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response</title>
        <description>From first day of treatment to documented disease progression as described by RECIST 1.1 criteria. Results are provided in nominal categories (CR, PR, SD, PD) as per RECIST.</description>
        <time_frame>Every 2 months for first 6 months, then every 3 months up to 2 years post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + High-Dose Ascorbate</title>
            <description>Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.&#xD;
Ascorbate: Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle&#xD;
Gemcitabine: Administered on Days 1, 8 and 15, after the infusion of ascorbate</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response</title>
          <description>From first day of treatment to documented disease progression as described by RECIST 1.1 criteria. Results are provided in nominal categories (CR, PR, SD, PD) as per RECIST.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Time from start of therapy (day 1, cycle 1) to documented disease progression or death due to any cause. Progression will be defined using the RECIST 1.1 guidelines. Results are provided in nominal categories (CR, PR, SD, PD) as per RECIST.</description>
        <time_frame>Every 2 months for first 6 months, then every 3 months up to 2 years post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + High-Dose Ascorbate</title>
            <description>Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.&#xD;
Ascorbate: Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle&#xD;
Gemcitabine: Administered on Days 1, 8 and 15, after the infusion of ascorbate</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Time from start of therapy (day 1, cycle 1) to documented disease progression or death due to any cause. Progression will be defined using the RECIST 1.1 guidelines. Results are provided in nominal categories (CR, PR, SD, PD) as per RECIST.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time from start of therapy (day 1, cycle 1) to death.</description>
        <time_frame>Every 2 months for first 6 months, then every 3 months up to 2 years post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + High-Dose Ascorbate</title>
            <description>Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.&#xD;
Ascorbate: Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle&#xD;
Gemcitabine: Administered on Days 1, 8 and 15, after the infusion of ascorbate</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from start of therapy (day 1, cycle 1) to death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events (AE) Per CTCAE 4.03</title>
        <description>Categorize and quantify adverse events from start of therapy (day 1, cycle 1) to end of study per (CTCAE) version 4.03.</description>
        <time_frame>Up to 30 days after completion of study treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine + High-Dose Ascorbate</title>
            <description>Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.&#xD;
Ascorbate: Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle&#xD;
Gemcitabine: Administered on Days 1, 8 and 15, after the infusion of ascorbate</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AE) Per CTCAE 4.03</title>
          <description>Categorize and quantify adverse events from start of therapy (day 1, cycle 1) to end of study per (CTCAE) version 4.03.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and lymphatic system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and nutrition disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and urinary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic and mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders and administration site conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected up to 30 days after completion of study treatment, up to 7 months</time_frame>
      <desc>Information about all adverse events, whether volunteered by the subject, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, were collected and recorded and followed as appropriate. Adverse events were followed for 30 days post last dose of drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine + High-Dose Ascorbate</title>
          <description>Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.&#xD;
Ascorbate: Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle&#xD;
Gemcitabine: Administered on Days 1, 8 and 15, after the infusion of ascorbate</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated early. Ten patients were enrolled in the first stage, and per protocol the study was terminated following interim analysis when 1 or fewer participants had a tumor response.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Assistant Professor</name_or_title>
      <organization>University of Iowa, Holden Comprehensive Cancer Center</organization>
      <phone>319-384-9497</phone>
      <email>varun-monga@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

